How to Integrate Competitor Analysis into Your IPO Prospectus

The Hong Kong Stock Exchange’s (HKEX) December 2024 consultation paper on GEM reform, which took effect on 1 January 2025, introduced a new “Market Capitalisation/Revenue Test” for listing applicants, lowering the minimum market capitalisation threshold from HKD 150 million to HKD 100 million while simultaneously requiring a demonstrable competitive advantage within the applicant’s industry vertical. This shift, codified in Chapter 11 of the GEM Listing Rules, directly elevates competitor analysis from a mere disclosure checkbox to a substantive test of listing eligibility. For a Main Board applicant under Chapter 8 of the Main Board Listing Rules, the SFC’s 2023 revised “Sponsor Regulation” (effective 31 March 2023) already mandates that a sponsor must exercise “reasonable due diligence to satisfy itself that the information in the prospectus is accurate and complete in all material respects,” with competitor positioning being a key area of scrutiny during the SFC’s post-IPO vetting of sponsor work. The market reality is unforgiving: a prospectus that fails to articulate a clear, data-backed competitive moat invites not only rejection but also subsequent regulatory liability. This article dissects the legal framework, structural mechanics, and disclosure strategies for integrating competitor analysis into an IPO prospectus for both Main Board and GEM listings, citing specific rules and providing a step-by-step methodology.

The Regulatory Mandate for Competitive Positioning

The HKEX and SFC do not treat competitor analysis as a discretionary marketing section. It is a mandatory component of the “Business” section in a prospectus, governed by specific disclosure requirements under the Listing Rules and the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32).

The Specific Rule Requirements

Under Main Board Listing Rules, Appendix D1A, paragraph 27(2) requires the prospectus to include “a description of the principal business of the issuer and its subsidiaries, including the main products or services provided and the markets in which they are sold.” Paragraph 27(4) further demands “a description of the competitive conditions in the markets in which the issuer operates.” This is not optional. For GEM applicants, the equivalent requirement is found in GEM Listing Rules Appendix D1A, paragraph 27(2) and (4), which mirror the Main Board provisions. The SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (the “Code of Conduct”), paragraph 17.6, obligates a sponsor to “ensure that all material information in the prospectus is accurate and complete in all material respects,” which includes assessing the issuer’s claims about its competitive position. The 2023 revision of the Sponsor Regulation (effective 31 March 2023) explicitly expanded the scope of due diligence to include “the issuer’s business model, its competitive advantages and the sustainability of its revenue streams,” as stated in the SFC’s “Consultation Conclusions on the Regulation of Sponsors” (December 2022).

The Consequences of Inadequate Disclosure

A failure to adequately disclose competitive risks has direct consequences. In the 2021 enforcement action against sponsor UBS AG and its affiliates (SFC, 2021), the SFC fined the sponsor HKD 375 million for failing to conduct adequate due diligence on the issuer’s business model and competitive position, specifically regarding its reliance on a single product category. The SFC’s statement noted that the sponsor “failed to identify and disclose material competitive risks that were known or should have been known.” More recently, in 2024, the HKEX published a “Listing Decision” (HKEX-LD123-2024) rejecting a biotech applicant’s Main Board filing under Chapter 18A, citing the prospectus’s failure to “provide a meaningful comparison with existing therapies in the same indication, rendering the disclosure of the issuer’s competitive position inadequate.” The decision explicitly referenced the requirement under paragraph 27(4) of Appendix D1A. These cases establish a clear precedent: a prospectus that presents a generic or self-serving competitive narrative without verifiable data is a regulatory liability.

Structuring the Competitor Analysis Section

The competitor analysis should not be a standalone appendix. It must be woven into the “Business” section of the prospectus, typically following the description of the issuer’s products or services and preceding the risk factors section. The structure must follow the “materiality principle” — only competitors that constitute a material threat or benchmark should be included.

Identifying the Competitive Universe

The first step is defining the competitive landscape. The prospectus must identify direct competitors (offering identical or substitutable products/services), indirect competitors (offering alternative solutions to the same customer need), and potential entrants (startups or large companies with adjacent capabilities). The HKEX’s “Guidance Letter on Disclosure of Business Models” (HKEX-GL86-16, updated 2023) advises that the issuer should “clearly state the basis for selecting the competitors and the time period over which the comparison is made.” Practically, this means the issuer must provide a market map. For a Hong Kong-listed consumer goods company, this could include a table listing each competitor, their market share (sourced from Euromonitor or Frost & Sullivan), their revenue range for the most recent financial year, and their geographic focus. The prospectus must cite the source of this data. A self-generated estimate without a named third-party source is insufficient. The SFC’s “Guidance Note on the Use of Market Research Reports in Prospectuses” (2022) explicitly states that “any market share data or competitive rankings must be supported by a report from an independent market research firm or a reputable trade association.”

Quantitative and Qualitative Metrics

The analysis must be both quantitative and qualitative. Quantitative metrics include market share (percentage and ranking), revenue growth rates (CAGR over 3 years), gross profit margins, and customer concentration. For a Main Board applicant under the Profit Test (HK$ 50 million profit in the most recent year), the prospectus must demonstrate that the issuer’s profit margin is sustainable relative to peers. For a GEM applicant under the new Market Capitalisation/Revenue Test (effective 1 January 2025), the issuer must show that its revenue growth trajectory is not an anomaly but a reflection of a durable competitive advantage. Qualitative metrics include brand recognition, intellectual property portfolio (number of granted patents and pending applications in Hong Kong, China, and other jurisdictions), regulatory approvals (e.g., NMPA, FDA, CE marking), and customer switching costs. The prospectus should present these in a comparative table, with the issuer’s metrics alongside the closest 3-5 competitors. The “Business” section of the 2024 prospectus of a Main Board-listed medical device company (HKEX: 9999.HK) provides a model: it included a table comparing the issuer’s product specifications, clinical trial endpoints, and pricing with the four leading competitors in the same indication, with all data sourced from published clinical studies and regulatory filings.

Addressing Competitive Risks

Every competitor analysis must conclude with a candid assessment of competitive risks. The “Risk Factors” section of the prospectus must include a specific sub-section titled “Risks Relating to the Issuer’s Competitive Position.” This sub-section must address scenarios such as: a competitor launching a superior product, a price war eroding margins, a new entrant with a disruptive technology, or a regulatory change that advantages a competitor. The HKEX’s “Guidance Letter on Risk Factor Disclosure” (HKEX-GL102-19) requires that risk factors be “specific to the issuer and its business, not generic.” A generic risk factor such as “the issuer faces competition” is insufficient. The issuer must name the competitor, describe the specific threat, and quantify the potential impact. For example: “Competitor A, which holds approximately 25% market share in the PRC market for [product], has announced a new product launch in 2026 that could reduce the issuer’s projected market share by 5-8 percentage points, based on analyst estimates from [named source].”

Data Sourcing and Verification

The credibility of the competitor analysis depends entirely on the verifiability of its data. The SFC and HKEX treat unsubstantiated claims as a failure of due diligence.

Primary and Secondary Sources

The prospectus must cite primary sources where possible. Primary sources include: the issuer’s own audited financial statements (for its own data), publicly filed financial statements of competitors (for Main Board-listed competitors in Hong Kong, China, or other jurisdictions), regulatory filings (e.g., FDA 510(k) clearances, NMPA approvals), and independent market research reports from named firms (e.g., Frost & Sullivan, Euromonitor, Gartner, IDC). Secondary sources, such as industry publications or analyst reports, can be used but must be clearly attributed. The SFC’s “Guidance Note on the Use of Market Research Reports in Prospectuses” (2022) stipulates that “any market research report cited in the prospectus must be commissioned by the issuer and prepared by an independent third party with a track record in the relevant industry.” The report must be dated within 12 months of the prospectus filing date. For a biotech applicant under Chapter 18A, the prospectus must cite published clinical trial results from peer-reviewed journals or regulatory databases (e.g., ClinicalTrials.gov) for competitor therapies.

The Role of the Sponsor

The sponsor bears the ultimate responsibility for verifying the competitor data. Under the SFC’s Code of Conduct, paragraph 17.6, the sponsor must “conduct reasonable due diligence to verify the accuracy of all material statements in the prospectus, including those relating to the issuer’s competitive position.” This typically involves: (1) reviewing the original source documents (e.g., market research reports, competitor financial statements); (2) conducting interviews with the issuer’s management, customers, and industry experts; and (3) cross-referencing the issuer’s claims against publicly available data. The sponsor should maintain a due diligence checklist specific to competitor analysis, with each data point traced to a source document. The HKEX’s “Guidance Letter on Sponsor Due Diligence” (HKEX-GL86-16, updated 2023) recommends that sponsors “document the rationale for selecting each competitor and the methodology used for the comparison.”

Handling Confidential or Proprietary Data

Issuers may be reluctant to disclose sensitive competitive data, such as pricing strategies or customer contracts. The prospectus must balance this concern with the need for material disclosure. The HKEX’s “Guidance Letter on Confidentiality” (HKEX-GL92-18) permits the redaction of commercially sensitive information in the prospectus, provided that the redacted information is not material to an investor’s understanding of the issuer’s competitive position. The sponsor must review the unredacted data and confirm to the HKEX in writing that the redacted information does not affect the materiality of the disclosure. The issuer must also be prepared to provide the unredacted data to the HKEX upon request during the vetting process.

Drafting and Presentation Mechanics

The language and presentation of the competitor analysis must adhere to the prospectus’s overall tone — factual, precise, and free of marketing hyperbole.

Language and Tone

The competitor analysis must be written in a neutral, analytical tone. Avoid phrases such as “the issuer is a market leader” without a supporting data point. Instead, use precise language: “Based on the Frost & Sullivan report commissioned by the issuer, the issuer held approximately 12.3% of the PRC market for [product] by revenue in 2024, ranking third among the six major participants.” The prospectus should avoid making forward-looking claims about the issuer’s future competitive position unless they are clearly identified as “forward-looking statements” and accompanied by a cautionary note, as required under the SFC’s “Guidelines on the Use of Forward-Looking Statements in Prospectuses” (2021). The cautionary note must state that actual results may differ materially due to, among other things, competitive actions.

Visual Presentation

Tables and charts are the most effective way to present competitor data. The prospectus should include a table with columns for: competitor name, market share (%), revenue (HKD million, most recent financial year), gross profit margin (%), key product/ service, and geographic focus. The table must be sourced. For example: “Source: Frost & Sullivan, 2024 Report.” The issuer’s own data should be presented in the same format for direct comparison. The “Business” section of the 2023 prospectus of a Main Board-listed logistics company (HKEX: 8888.HK) included a bar chart showing the issuer’s market share trend over 5 years against the average of its three largest competitors, with the data clearly labelled. The HKEX does not prescribe a specific format, but the “Guidance Letter on Presentation of Information in Prospectuses” (HKEX-GL99-19) advises that “any graphical representation must be clear, accurate, and not misleading.” The sponsor must verify that the chart does not distort the data (e.g., using a truncated y-axis that exaggerates a small difference).

Cross-Referencing to Risk Factors

The competitor analysis in the “Business” section must be cross-referenced to the specific risk factors in the “Risk Factors” section. The prospectus should include a sentence at the end of the competitor analysis: “For a discussion of the risks associated with the issuer’s competitive position, see ‘Risk Factors — Risks Relating to the Issuer’s Competitive Position’.” This ensures that the investor reading the business description is immediately directed to the corresponding risks. The cross-reference must be explicit, not generic.

Actionable Takeaways

1. Integrate competitor analysis directly into the “Business” section of the prospectus, not as a separate appendix, and ensure it addresses the specific requirements under Main Board Listing Rules Appendix D1A, paragraph 27(4) or GEM Listing Rules Appendix D1A, paragraph 27(4), as applicable.
2. Commission an independent market research report from a named third party (e.g., Frost & Sullivan, Euromonitor) dated within 12 months of the prospectus filing, and cite it as the primary source for all market share and competitive ranking data.
3. Structure the analysis as a comparative table with the issuer and its 3-5 closest competitors, using quantitative metrics (market share, revenue, gross margin) and qualitative metrics (IP portfolio, regulatory approvals), with all data sourced to a verifiable document.
4. Draft a specific “Risks Relating to the Issuer’s Competitive Position” sub-section in the “Risk Factors” section that names each material competitor, describes the specific threat, and quantifies the potential impact, rather than using generic language.
5. Maintain a sponsor due diligence checklist for competitor analysis, with each data point traced to a source document, and be prepared to provide unredacted data to the HKEX upon request during the vetting process.